The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study by Martin-Merino, E, Calderón-Larrañaga, A, Hawley, S, Poblador-Plou, B, Llorente, A, Petersen, I, Prieto-Alhambra, D

“…<strong>Methods:</strong> New users of AOM (alendronic acid, other bisphosphonates, strontium ranelate, selective estrogen receptor modulators, teriparatide, or denosumab) aged ≥50 years during 1998–2014 were identified in two Spanish (the Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [BIFAP] and EpiChron cohort) and one UK (Clinical Practice Research Datalink [CPRD]) EMR. …”

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK... by Khalid, S, Calderon-Larrañaga, S, Hawley, S, Ali, M, Judge, A, Arden, N, Van Staa, T, Cooper, C, Javaid, M, Prieto-Alhambra, D

“…Users of alendronate (reference group) were compared to those of (1) OBP, (2) strontium ranelate (SR), and (3) selective estrogen receptor modulators (SERMs), after matching on baseline characteristics using propensity scores. …”